First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Asset Resilience Ratio
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued asset resilience ratio. First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has an Asset Resilience Ratio of 13.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of First Tracks Biotherapeutics, Inc. Ordin to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Asset resilience ratio of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. This chart shows how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's Asset Resilience Ratio has changed over time. Read TRAXV current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TRAXV total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.99 Million | 13.07% |
| Total Liquid Assets | $37.99 Million | 13.07% |
Asset Resilience Insights
- Moderate Liquidity: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued has 13.07% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Industry Peers by Asset Resilience Ratio
Compare First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Asset Resilience Ratio by Year (2023–2024)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued asset resilience ratio by year from 2023 to 2024. The table below shows the annual Asset Resilience Ratio data for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 59.36% | $262.29 Million | $441.89 Million | -20.56pp |
| 2023-12-31 | 79.92% | $354.94 Million | $444.11 Million | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more